AlbertoAChiapporiMD

Assistant Professor, Oncologic Sciences, USF-Morsani

Overview of Dr. Chiappori

Dr. Alberto Chiappori is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Cayetano Heredia University and has been in practice 28 years. Dr. Chiappori accepts several types of health insurance, listed below. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(440) 678-2439

Fax+1 813-979-3027

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1997
Southern Illinois UniversityResidency, Internal Medicine, 1990 - 1993
Cayetano Heredia UniversityClass of 1989

Certifications & Licensure

FL State Medical License 2001 - 2025
KY State Medical License 1997 - 2002
IL State Medical License 1990 - 1999
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 2
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem Start of enrollment: 2007 Jun 01
Terminated
Phase 2
Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC) Start of enrollment: 2008 Apr 01
Completed
Phase 2
Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS) Start of enrollment: 2011 Jan 01
Completed
Phase 2
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer Start of enrollment: 2012 Mar 26
Completed
Phase 1, Phase 2
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2013 Dec 31
Completed
Phase 1
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) Start of enrollment: 2018 Mar 15
Terminated
Phase 2
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer Start of enrollment: 2019 Jun 06
Active, not recruiting
Phase 1
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Start of enrollment: 2020 Nov 23
Terminated
Phase 1
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer Start of enrollment: 2022 Mar 30
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

78 citations
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
Gerold Bepler, K. Eric Sommers, Alan B. Cantor, Xueli Li, Anupama Sharma
Journal of Thoracic Oncology. 2008-10-01
72 citations
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer.
Nitin Roper, Moises J. Velez, Alberto Chiappori, Yoo Sun Kim, Jun Wei
Nature Communications. 2021-06-23
651 citations
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami
The New England Journal of Medicine. 2017-11-16

Journal Articles

Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC
David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine

Lectures

Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Mesothelioma Find Out About Explores New Remedy When Chemotherapy FailsAugust 27th, 2021
Mesothelioma Study Explores New Treatment When Chemotherapy FailsAugust 26th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment